Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12238937 | PMC |
| http://dx.doi.org/10.1093/oncolo/oyaf122 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
How the addition of selinexor/bortezomib/dexamethasone as a Category 1 recommendation may erode outcomes.
Oncologist
July 2025
Division of Hematology, Huntsman Cancer Center, University of Utah, Salt Lake City, UT, USA.
Selinexor-Bortezomib-Dexamethasone: A Review in Previously Treated Multiple Myeloma.
Target Oncol
March 2023
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Selinexor [Nexpovio (EU); Xpovio (USA)] is a first-in-class, selective exportin-1 inhibitor. Oral selinexor once weekly in combination with subcutaneous bortezomib once weekly and oral dexamethasone twice weekly (selinexor-bortezomib-dexamethasone) is approved in the EU and USA for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. In the open-label, randomized, phase 3 BOSTON trial, this regimen significantly prolonged progression-free survival (PFS) compared with the standard bortezomib-dexamethasone regimen in patients with previously treated multiple myeloma.
View Article and Find Full Text PDFNetwork Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma.
J Health Econ Outcomes Res
August 2021
Karyopharm Therapeutics, Newton, MA, USA.
Despite the availability of new treatments, multiple myeloma (MM) is an incurable cancer with nearly all patients relapsing and undergoing multiple lines of treatment. Performing head-to-head comparisons of all treatment options is not feasible. Thus, network meta-analyses play an important role in allowing health-care decision makers to compare the effectiveness of treatment options.
View Article and Find Full Text PDFCost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial.
Pharmacoeconomics
November 2021
Karyopharm Therapeutics, Newton, MA, USA.
Background And Objective: Nearly all patients with multiple myeloma undergo multiple rounds of therapy. The phase III BOSTON trial of once-weekly selinexor and once-weekly bortezomib with dexamethasone (XVd) vs twice-weekly bortezomib and dexamethasone (Vd) is the basis for this cost-effectiveness analysis in previously treated multiple myeloma from a US commercial payer perspective over a lifetime horizon.
Methods: A partitioned survival model enabled use of direct overall survival and progression-free survival curves from BOSTON to generate four health states for XVd and Vd: progression-free survival on treatment, progression-free survival off treatment, post-progression, and mortality.